Zenas BioPharma, Inc. ZBIO
- obexelimab — IgG4-Related Disease NDA Submitted
- obexelimab — Relapsing Multiple Sclerosis Phase 2
- obexelimab — Systemic Lupus Erythematosus Phase 2
- ZB014 Preclinical
FcγRIIb (1 companies · 4 programs)
Companies with an active program directed at FcγRIIb.